Reactive oxygen species and epidermal growth factor are antagonistic cues controlling SHP-2 dimerization

Molecular and Cellular Biology

Volumn 32, Issue 10, 2012, Pages 1998-2009

  Nardozza, Aurelio Pio ^a   D'Orazio, Melania ^b   Trapannone, Riccardo ^a   Corallino, Salvatore ^a   Filomeni, Giuseppe ^a,b   Tartaglia, Marco ^c   Battistoni, Andrea ^a   Cesareni, Gianni ^a,d   Castagnoli, Luisa ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DIMER; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; REACTIVE OXYGEN METABOLITE;

ARTICLE; BIOCHEMISTRY; CATALYSIS; CELL STIMULATION; CONTROLLED STUDY; DIMERIZATION; DISULFIDE BOND; EMBRYO; ENZYME ACTIVITY; ENZYME CONFORMATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN FUNCTION;

DIMERIZATION; EPIDERMAL GROWTH FACTOR; HEK293 CELLS; HUMANS; MUTATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; REACTIVE OXYGEN SPECIES;

EID: 84861379047     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06674-11     Document Type: Article

References (52)

1. Adler V, Yin Z, Tew KD, Ronai Z. 1999. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 18:6104-6111.
2. Agazie YM, Hayman MJ. 2003. Development of an efficient "substratetrapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates. J. Biol. Chem. 278:13952-13958.
3. Benezra R. 1994. An intermolecular disulfide bond stabilizes E2A homodimers and is required forDNAbinding at physiological temperatures. Cell 79:1057-1067.
4. Bennett AM, Hausdorff SF, O'Reilly AM, Freeman RM, Neel BG. 1996. Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol. Cell. Biol. 16:1189-1202.
5. Chan G, Kalaitzidis D, Neel BG. 2008. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 27:179-192.
6. Chen CY, Willard D, Rudolph J. 2009. Redox regulation of SH2-domain-containing protein tyrosine phosphatases by two backdoor cysteines. Biochemistry 48:1399-1409.
7. Cunnick JM, Mei L, Doupnik CA, Wu J. 2001. Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2. J. Biol. Chem. 276:24380-24387.
8. Dance M, Montagner A, Salles JP, Yart A, Raynal P. 2008. The molecular functions of Shp2 in the Ras/mitogen-activated protein kinase (ERK1/2) pathway. Cell. Signal. 20:453-459.
9. den Hertog J, Ostman A, Bohmer FD. 2008. Protein tyrosine phosphatases: regulatory mechanisms. FEBS J. 275:831-847.
10. Dornan S, et al. 2002. Differential association of CD45 isoforms with CD4 and CD8 regulates the actions of specific pools of p56lck tyrosine kinase in T cell antigen receptor signal transduction. J. Biol. Chem. 277:1912-1918.
11. Ferrari E, et al. 2011. Identification of new substrates of the proteintyrosine phosphatase PTP1B by Bayesian integration of proteome evidence. J. Biol. Chem. 286:4173-4185.
12. Finkel T. 1998. Oxygen radicals and signaling. Curr. Opin. Cell Biol. 10:248-253.
13. Hanna N, et al. 2006. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett. 580: 2477-2482.
14. Hilpert K, Winkler DF, Hancock RE. 2007. Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion. Nat. Protoc. 2:1333-1349.
15. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. 1998. Crystal structure of the tyrosine phosphatase SHP-2. Cell 92:441-450.
16. Hornbeck PV, Chabra I, Kornhauser JM, Skrzypek E, Zhang B. 2004. PhosphoSite: a bioinformatics resource dedicated to physiological protein phosphorylation. Proteomics 4:1551-1561.
17. Huang Q, et al. 2002. The novel role of the C-terminal region of SHP-2. Involvement of Gab1 and SHP-2 phosphatase activity in Elk-1 activation. J. Biol. Chem. 277:29330-29341.
18. Jorgensen C, et al. 2009. Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells. Science 326: 1502-1509.
19. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG. 2005. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J. Biol. Chem. 280:30984-30993.
20. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. 2006. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281:6785-6792.
21. Lesage F, et al. 1996. Dimerization of TWIK-1 K+ channel subunits via a disulfide bridge. EMBO J. 15:6400-6407.
22. Marin TM, et al. 2011. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest. 121:1026-1043.
23. Martinelli S, et al. 2008. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum. Mol. Genet. 17:2018-2029.
24. Matozaki T, Murata Y, Saito Y, Okazawa H, Ohnishi H. 2009. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 100:1786-1793.
25. Matozo HC, et al. 2007. Low-resolution structure and fluorescence anisotropy analysis of protein tyrosine phosphatase eta catalytic domain. Biophys. J. 92:4424-4432.
26. Meng TC, Fukada T, Tonks NK. 2002. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol. Cell 9:387-399.
27. Mesecke N, et al. 2005. A disulfide relay system in the intermembrane space of mitochondria that mediates protein import. Cell 121:1059-1069.
28. Montagner A, et al. 2005. A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J. Biol. Chem. 280:5350-5360.
29. Neel BG, Gu H, Pao L. 2003. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28:284-293.
30. Oishi K, et al. 2009. Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. Hum. Mol. Genet. 18:193-201.
31. O'Reilly AM, Pluskey S, Shoelson SE, Neel BG. 2000. Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Mol. Cell. Biol. 20:299-311.
32. Orton RJ, et al. 2009. Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway. BMC Syst. Biol. 3:100.
33. Ozawa T, Nakata K, Mizuno K, Yakura H. 2007. Negative autoregulation of Src homology region 2-domain-containing phosphatase-1 in rat basophilic leukemia-2H3 cells. Int. Immunol. 19:1049-1061.
34. Rushworth LK, Hindley AD, O'Neill E, Kolch W. 2006. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 26:2262-2272.
35. Saxton TM, et al. 1997. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. 16:2352-2364.
36. Scherz-Shouval R, et al. 2007. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4.EMBOJ. 26:1749-1760.
37. 2-terminal mitogen-activated protein kinases. J. Biol. Chem. 273:4904-4908.
38. Shi ZQ, Yu DH, Park M, Marshall M, Feng GS. 2000. Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol. Cell. Biol. 20:1526-1536.
39. Sugimoto S, Wandless TJ, Shoelson SE, Neel BG, Walsh CT. 1994. Activation of the SH2-containing protein tyrosine phosphatase, SHPTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. J. Biol. Chem. 269:13614-13622.
40. 2 for platelet-derived growth factor signal transduction. Science 270:296-299.
41. Takada T, et al. 1998. Roles of the complex formation of SHPS-1 with SHP-2 in insulin-stimulated mitogen-activated protein kinase activation. J. Biol. Chem. 273:9234-9242.
42. Tang TL, Freeman RM, Jr, O'Reilly AM, Neel BG, Sokol SY. 1995. The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. Cell 80:473-483.
43. Tapia V, et al. 2008. Evaluating the coupling efficiency of phosphorylated amino acids for SPOT synthesis. J. Pept. Sci. 14:1309-1314.
44. Tartaglia M, Gelb BD. 2010. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann. N. Y. Acad. Sci. 1214:99-121.
45. Tartaglia M, et al. 2006. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet. 78:279-290.
46. Tartaglia M, et al. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29: 465-468.
47. Tartaglia M, et al. 2003. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 34:148-150.
48. Tertoolen LG, et al. 2001. Dimerization of receptor protein-tyrosine phosphatase alpha in living cells. BMC Cell Biol. 2:8.
49. Voena C, et al. 2007. The tyrosine phosphatase Shp2 interacts with NPMALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 67:4278-4286.
50. Vogel W, Ullrich A. 1996. Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584. Cell Growth Differ. 7:1589-1597.
51. Wang N, et al. 2006. Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling. J. Biol. Chem. 281: 21878-21883.
52. You M, Yu DH, Feng GS. 1999. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol. 19:2416-2424.